Funding

1U01 CA236215   (Sloan AE*, Gerson S, & Gilbert M Co-PIs)                     

Chemoprotection & Immune Remodeling after Hematopoietic Progenitor Cell Gene

Therapy for Glioblastoma. The overall goals of this proposal are two-fold: 1). To expand an innovative and ongoing and active phase I clinical trial at the Case Comprehensive Cancer Center using genetically engineered blood cells to improve tolerance to chemotherapy in patients with newly diagnosed GBM to the NIH Clinical Center; and 2) to define the effects of this treatment on the immune system. The anticipated benefit of this collaboration will be both improved understanding of the interaction of GBM with the immune system as well as the development of new approaches to treating this disease.

1 RO1CA217956-01 (Brady-Kalnay S*, Gastenau M & Sloan AE Co-PIs) 

A Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain tumors.   The overall goal of this proposal is to further develop and imaging agent targeting PTPu for fluorescence-guided resection (FGR) of invasive glioma.

R21 CA256573 (Sloan AE* and McCormick T, Co-PIs)              

Differential Diagnosis of recurrent GBM versus Radiation Necrosis using MDSC biomarkers

This grant focuses on a novel hematological biomarker of tumor grade and response to treatment.

1P01 CA245705-01 (Lathia*/Barnholtz-Sloan, MPI)                                      

Sex-based Differences in Glioma: This Program Project, focuses on the confluence of sex differences in tumor cells and the micro-environment, emerging from oncogenic events and normal sexual differentiation, underlie mechanistic differences in gliomagenesis and disease outcome in order to identify sex-specific mechanisms that drive GBM.  

Investigator Initiated Grant (Sloan AE, PI)  NCT 03277638                   

Case 3316:  Multicenter Phase I/II Study of Laser Interstitial Thermotherapy (LITT) combined with checkpoint inhibitor for Difficult to Access (DTA) High-Grade Glioma (HGG).    The goal of this project is to assess safety and feasibility of combining LITT and a novel oral checkpoint inhibitor for the treatment of difficult to access (DTA) high grade gliomas.

Coulter Translational Research Grant (Basilion, Brady-Kalnay*,Sloan AE Co-PIs)   

Novel Molecular Imaging Agent for Surgical Resection of Invasive Brain Tumors.  The goal is to perform pre-clinical toxicity studies to gain FDA approval for a phase 0/I first in human study to be led by Dr. Sloan.

Translational Research Grant (Sloan AE, PI)                                            

Kimble Family Foundation,                                                                                                                          

Assessment of Intra-Tumoral Heterogeneity. The goal of this project is to characterize differences in intra-tumoral heterogeneity in patients with GBM using radiological and genomic methodologies

​

D.C. Austin Fund (Sloan AE, PI)                                                                                                                

Translational Research in Glioma. The goal of this private foundation grant is to perform translational research focusing on glioma initiating cells (GICs).

Ferry Family Foundation (Sloan AE, PI)                     

Biomarkers for Immunotherapy of malignant Brain Tumors. The goal of the grant is to fund research on biomarkers associated with treatment response in patients undergoing immunotherapy for malignant brain tumors.

Gerald Kaufman Jr. Foundation (Sloan AE, PI)

Immunotherapy for malignant brain tumors.   The goal of the grant is to fund research in immunotherapy for malignant brain tumors.  

Role: PI

Center of Excellence for Translational Neuro-Oncology (CETNO)     1/1/19-12/31/23                  

University Hospitals Seidman Cancer Center

The goal of the center is to mentor faculty and resident to generate innovative early stage clinical trials based on ongoing basic and translational research at UH, CWRU, the Case Comprehensive Cancer Center, Cleveland State University and other academic and commercial entities in the Cleveland Metro Area.

University Hospitals-Ohio Third Frontier Technology Validation Fund (PI Sloan A)                    

Validation of DVI as biomarker of Glioma Recurrence.   This study will assess DVI longitudinally across glioma patients and fund development of proprietary biomarker.

Case Western Reserve University Institute for Computational Biology (Brady-Kalnay*, Badve and Sloan AE Co-PIs)                                                                                                     

Mechanisms of Detection of Glioma Progression Using Multiscale Integration                           

This grant will assess MRF for characterizing response to treatment in pre-clinical and clinical models.                                                                                                                                           

Brain Tumor Association of the Midwest (BTAM) (Hoffman H: PI; Sloan AE, Mentor)                                                                 

Platelet and Glioma Stem Cell Interaction is Facilitated by Glioma Stem Cell            

Expression of Platelet Adhesion Receptors.  This study will characterize the interaction between Platelets and Glioma Stem Cells.